首页> Drug, healthcare and patient safety> Evaluating cardiac risk: exposure response analysis in early clinical drug development.

Evaluating cardiac risk: exposure response analysis in early clinical drug development.

导出 LinkOut

翻译打印收藏纠错

第一作者： Julie,Grenier

第一单位： Data Management and Biometric, Celerion, Montreal, QC, Canada.

作者： Julie,Grenier ^[1] ; Sabina,Paglialunga ^[2] ; Bruce H,Morimoto ^[2] ; Robert M,Lester ^[3]

作者单位： Data Management and Biometric, Celerion, Montreal, QC, Canada. ^[1] Scientific Affairs, Celerion, Lincoln, NE, USA. ^[2] Global Clinical Research, Celerion, Tempe, AZ, USA. ^[3]

关键词 QT/QTc assay sensitivity concentration-effect modeling intensive ECG collection intersection union test moxifloxacin positive control thorough QT study

DOI 10.2147/DHPS.S133286

PMID 29713203

发布时间 2023-11-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Drug, healthcare and patient safety

2018年10卷

27-36页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

点击下载本期目录封面

Drug, healthcare and patient safety

2018年10卷

27-36页

检索历史清除

Evaluating cardiac risk: exposure response analysis in early clinical drug development.

Drug, healthcare and patient safety

相似文献

Drug, healthcare and patient safety

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Evaluating cardiac risk: exposure response analysis in early clinical drug development.

Drug, healthcare and patient safety

相似文献

Drug, healthcare and patient safety

相关期刊

检索历史清除